JP2016502504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502504A5 JP2016502504A5 JP2015536163A JP2015536163A JP2016502504A5 JP 2016502504 A5 JP2016502504 A5 JP 2016502504A5 JP 2015536163 A JP2015536163 A JP 2015536163A JP 2015536163 A JP2015536163 A JP 2015536163A JP 2016502504 A5 JP2016502504 A5 JP 2016502504A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- conjugate
- seq
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000562 conjugate Substances 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 10
- 102000004965 antibodies Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 108091008116 antibody drug conjugates Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712928P | 2012-10-12 | 2012-10-12 | |
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| US61/712,924 | 2012-10-12 | ||
| US61/712,928 | 2012-10-12 | ||
| US201361784233P | 2013-03-14 | 2013-03-14 | |
| US201361784270P | 2013-03-14 | 2013-03-14 | |
| US201361784249P | 2013-03-14 | 2013-03-14 | |
| US61/784,233 | 2013-03-14 | ||
| US61/784,270 | 2013-03-14 | ||
| US61/784,249 | 2013-03-14 | ||
| PCT/EP2013/071343 WO2014057115A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502504A JP2016502504A (ja) | 2016-01-28 |
| JP2016502504A5 true JP2016502504A5 (US07794700-20100914-C00152.png) | 2016-12-01 |
Family
ID=49552324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536163A Pending JP2016502504A (ja) | 2012-10-12 | 2013-10-11 | ピロロベンゾジアゼピン−抗体結合体 |
Country Status (21)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| AU2012311505B2 (en) | 2011-09-20 | 2016-09-29 | Medimmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates |
| CN108164551A (zh) | 2011-10-14 | 2018-06-15 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
| ES2530968T3 (es) | 2012-10-12 | 2015-03-09 | Spirogen Sarl | Pirrolobenzodiazepinas y conjugados de las mismas |
| CA2885305C (en) | 2012-10-12 | 2019-11-12 | Spirogen Sarl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| CN110256469B (zh) | 2012-10-12 | 2022-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CA2894961C (en) | 2012-12-21 | 2020-09-15 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| CA2901941C (en) | 2013-03-13 | 2020-04-07 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| CN106687141A (zh) * | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| DK3191135T3 (da) | 2014-09-12 | 2020-10-12 | Genentech Inc | Anti-HER2-antistoffer og immunokonjugater |
| RU2727663C2 (ru) * | 2014-09-17 | 2020-07-22 | Дженентек, Инк. | Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины |
| CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| TWI778491B (zh) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| RS62343B1 (sr) | 2017-02-08 | 2021-10-29 | Adc Therapeutics Sa | Pirolobenzodiazepin-antitelo konjugati |
| AU2018217926B2 (en) | 2017-02-08 | 2019-10-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| JP2020517609A (ja) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | ピロロベンゾジアゼピン複合体 |
| EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
| WO2018193104A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
| WO2018229218A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd25 adc |
| SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
| US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
| CA3134403A1 (en) * | 2019-03-25 | 2020-10-01 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP4013494A1 (en) | 2019-08-12 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2270010T3 (da) * | 2004-03-01 | 2012-05-14 | Spirogen Ltd | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-on-derivater som vigtige mellemprodukter i fremstillingen af c2-substituerede pyrrolobenzodiazepiner |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP2445539A4 (en) * | 2009-06-26 | 2015-05-20 | Five Prime Therapeutics Inc | VALIDATION OF TARGETS OF THERAPEUTIC ANTIBODIES AND IN VIVO SCREENING |
| US8697688B2 (en) * | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2011130613A1 (en) * | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| ES2430567T3 (es) * | 2010-04-15 | 2013-11-21 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados de las mismas |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| WO2012153193A2 (en) * | 2011-05-08 | 2012-11-15 | Legochem Biosciences, Inc. | Protein-active agent conjugates and method for preparing the same |
| PT2750713E (pt) * | 2011-10-14 | 2016-01-20 | Genentech Inc | Pirrolobenzodiazepinas e conjugados das mesmas |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Application Discontinuation
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en active Application Filing
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-08-17 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
